相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Over-expression of EGFR regulated by RARA contributes to 5-FU resistance in colon cancer
Xin-Yue Gu et al.
AGING-US (2020)
The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge
Yi-Chen Zhang et al.
SCIENCE BULLETIN (2019)
Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing
Tiziano Ingegnere et al.
FRONTIERS IN IMMUNOLOGY (2019)
Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges
Luyao Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Cell-based immunotherapy approaches for multiple myeloma
Katharina Kriegsmann et al.
BRITISH JOURNAL OF CANCER (2019)
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
Yan Liu et al.
AGING-US (2019)
Oncogenic functions of protein kinase D2 and D3 in regulating multiple cancer-related pathways in breast cancer
Yan Liu et al.
CANCER MEDICINE (2019)
CAR-Expressing Natural Killer Cells for Cancer Retargeting
Stephan Kloess et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2019)
Chimeric antigen receptor T-cell therapies for lymphoma
Jennifer N. Brudno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li et al.
CELL STEM CELL (2018)
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Yanyu Pang et al.
MOLECULAR CANCER (2018)
Targeted peptide-Au cluster binds to epidermal growth factor receptor (EGFR) in both active and inactive states: a clue for cancer inhibition through dual pathways
Peng Zhang et al.
SCIENCE BULLETIN (2018)
Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells
Toshiharu Murakami et al.
ANTICANCER RESEARCH (2018)
Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
Aleksandra Simiczyjew et al.
CANCERS (2018)
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
Daniel Shepshelovich et al.
CANCER MEDICINE (2018)
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
Qing Zhang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy
Yuan Hu et al.
ACTA PHARMACOLOGICA SINICA (2018)
Oncogenic Protein Kinase D3 Regulating Networks in Invasive Breast Cancer
Yan Liu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
Kevin G. Pinz et al.
ONCOTARGET (2017)
Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment
Mei Liu et al.
CELL PROLIFERATION (2016)
Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor
Chiara Corrado et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Driving CAR T-cells forward
Hollie J. Jackson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
Xilin Chen et al.
ONCOTARGET (2016)
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Ace J. Hatch et al.
CANCER MEDICINE (2016)
Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women
E. Tilch et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
V. Secq et al.
BRITISH JOURNAL OF CANCER (2014)
Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer
Hiroki Nakajima et al.
BREAST CANCER (2014)
Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients
Yoonjung Kim et al.
PLOS ONE (2013)
Integrin α5β1 simultaneously controls EGFR-dependent proliferation and Akt-dependent pro-survival signaling in epidermoid carcinoma cells
Galina E. Morozevich et al.
AGING-US (2012)
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
Libero Santarpia et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Role of epidermal growth factor receptor in breast cancer
Hiroko Masuda et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
EGFR is involved in control of gastric cell proliferation through activation of MAPK and Src signalling pathways in early-weaned rats
L. H. Osaki et al.
CELL PROLIFERATION (2011)
Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy
Yvonne Hui-Fang Teng et al.
BREAST CANCER RESEARCH (2011)
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
William Jacot et al.
BREAST CANCER RESEARCH (2011)
Triple negative breast cancers: Clinical and prognostic implications
S.J. Dawson et al.
EUROPEAN JOURNAL OF CANCER (2009)
The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer
Mandira Ray et al.
ONCOLOGIST (2009)
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers
Tatsuya Toyama et al.
BMC CANCER (2008)
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2008)
Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis
Michael Vibo Grandal et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation
G. Brockhoff et al.
CELL PROLIFERATION (2007)
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines
D. W. Rusnak et al.
CELL PROLIFERATION (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
EGFR associated expression profiles vary with breast tumor subtype
Katherine A. Hoadley et al.
BMC GENOMICS (2007)
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
J. S. Reis et al.
JOURNAL OF PATHOLOGY (2006)
分享论文
